Synlogic jumps on positive trial data for blood disorder treatment

Synlogic

18/10/2022 13:31

** Shares of drugmaker Synlogic Inc  SYBX.O  rise ~11% to
$1.2 before the bell
    ** Co reports positive data from mid-stage trial testing
experimental drugs SYNB1618 and SYNB1934 in treating
phenylketonuria (PKU)  urn:newsml:reuters.com:*:nGNX6Hd7wR
    ** PKU is an inherited disorder that increases levels of a
substance called phenylalanine in blood, which can lead to brain
damage, intellectual disabilities and behavioral symptoms or
seizures
    ** SYBX expects initiation of late-stage study for SYNB1934
in first half of 2023
    ** Up to Monday's close, stock down 55.4% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))